Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
AIM ImmunoTech Inc.'s Drug Ampligen Awarded FDA's Orphan Drug Designation Status for the Treatment of Pancreatic Cancer
09:40am, Monday, 21'st Dec 2020
OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, vir
AIM ImmunoTech Inc.'s Drug Ampligen Awarded FDA's Orphan Drug Designation Status for the Treatment of Pancreatic Cancer
06:45am, Monday, 21'st Dec 2020
OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, vir
Why These 3 Health Care Stocks Are Trading Higher Today
11:01am, Wednesday, 25'th Nov 2020
AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with cancer and
OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the di
AIM ImmunoTech Provides Third Quarter 2020 Business Update
07:30am, Friday, 13'th Nov 2020
OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, vir
Early Onset Therapy May Be Key to COVID Long Hauler Syndrome Early Onset Therapy May Be Key to COVID Long Hauler Syndrome
BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year
10:00am, Friday, 30'th Oct 2020
TAMPA, Fla. and OCALA, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioFlorida has announced Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech Inc. (NYSE American: AIM), as its Weaver H. Gaines E
AIM ImmunoTech (AIM) Investor Presentation - Slideshow
01:38pm, Friday, 04'th Sep 2020
The following slide deck was published by AIM ImmunoTech Inc. in conjunction with this event..
We're Hopeful That AIM ImmunoTech (NYSEMKT:AIM) Will Use Its Cash Wisely
01:18pm, Monday, 17'th Aug 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
AIM ImmunoTech Provides Second Quarter 2020 Business Update and Reports Progress in Both COVID-19 and Cancer Trials
10:55am, Monday, 17'th Aug 2020
Phase 1/2a trial of Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19 is on track for enrollmentOCALA, FL / ACCESSWIRE / August 17, 2020 / AIM ImmunoTech (NYSE American:
LD Micro Announces Preliminary List of Presenters for the LD 500
01:00pm, Wednesday, 05'th Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin
49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020
12:00pm, Monday, 03'rd Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 3, 2020 / The SNN Network Virtual Conference will take place on August 3rd \\- 6th, 2020, where 49 SmallCap, MicroCap and NanoCap public companies will be present
AIM ImmunoTech to Present at the SNN Network Virtual Investor Conference on Monday, August 3rd
10:55am, Monday, 27'th Jul 2020
OCALA, FL / ACCESSWIRE / July 27, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it will be presenting at the SNN Network Virtual Investor Conference on Monday, August 3, 2020 at 1:30
OCALA, FL / ACCESSWIRE / July 9, 2020 / AIM ImmunoTech (NYSE AMERICAN:AIM), today announced that it has entered into a clinical trial agreement (CTA) with Roswell Park Comprehensive Cancer Center to s
OCALA, FL / ACCESSWIRE / July 6, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that is has signed a material transfer and research agreement with Japan's National Institute of Infectious
